Viatris Inc vs Advanced Drainage Systems Inc — how do they compare? Viatris Inc trades at $17.35 (market cap $20.03B), while Advanced Drainage Systems Inc trades at $125.66 (market cap $9.52B). The key difference: Viatris Inc is far larger — about 2.1× Advanced Drainage Systems Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Advanced Drainage Systems Inc for 43 Days on average.
| VTRS | WMS | |
|---|---|---|
Market Cap | $20.03B | $9.52B |
Volume | 14,109,977 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $18.27 | $175.38 |
52-Week Low | $9.74 | $125.33 |
Typical Hold Time | 57 Days | 43 Days |
Enterprise Value | $32.15B | $11.12B |
Dividend Yield | 2.75% | 0.63% |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Advanced Drainage Systems (WMS) trades at $126.36, up 0.22% with a bearish technical signal despite strong fundamental performance. The company reported Q2 2026 EPS of $2.49, beating estimates by 18.6%, continuing a trend of earnings outperformance. Key financial metrics show robust profitability with 14% net income margin and 24.9% ROE, though cash flow turned negative in 2025 due to increased capital investments. Recent news highlights sustainability initiatives and institutional positioning changes.
WMS presents a compelling investment case with consistent earnings beats and strong analyst support ($188.70 price target), but faces near-term technical headwinds and cash flow pressures from aggressive expansion. The stock's current valuation at 21.5x P/E appears reasonable given growth prospects, though investors should monitor execution of NDS integration and capital allocation strategy.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →